Gender-Atypical Mental Illness as Male Gender Threat.

The present study examined whether men view gender-atypical (i.e., feminine) psychological disorders as threats to their gender status.

Gender dichotomization at the level of ingroup identity: what it is, and why men use it more than women.

In 5 studies (N = 756), we show that men's relative to women's gender ingroup identities are characterized by greater levels of gender dichotomization, a tendency to distance masculine from feminine traits. We demonstrate further that men's gender dichotomization is motivated, in part, by a need to eschew femininity from their ingroup identity to bolster a precarious gender status. Studies 1-3 establish and replicate the basic effect, and rule out alternative explanations (positivity, projection, status striving) for men's tendency to dichotomize more than women.

Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.

Background: Combinations of anthracyclines, taxanes and gemcitabine have shown high activity in breast cancer. This trial was designed to evaluate a modified combination regimen as primary chemotherapy. Non-pegylated liposomal doxorubicin (NPLD) was used instead of conventional doxorubicin to improve cardiac safety.

Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.

The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with histologically confirmed stage II or III breast cancer were treated with liposomal doxorubicin (50-60 mg/m2) and docetaxel (60-75 mg/m2) on day 1, and gemcitabine as 4-h infusion (350-400 mg/m2) on day 4.

Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.

Purpose: To assess the efficacy and safety of primary systemic treatment with doxorubicin and paclitaxel in patients with early breast cancer.

Patients And Methods: Forty patients with newly diagnosed, histologically confirmed breast cancer (T2, N0-1, M0) received primary chemotherapy with doxorubicin (60 mg/m2) and paclitaxel (200 mg/m2) in 3-week intervals for up to four courses.

Results: A total of 151 cycles were administered.